Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Cervical Cancer

  Free Subscription


Articles published in Gynecol Oncol

Retrieve available abstracts of 119 articles:
HTML format



Single Articles


    May 2025
  1. CHO WK, Park W, Kim SW, Lee KK, et al
    Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: prospective phase 2 trial (POHIM_RT study).
    Gynecol Oncol. 2025;198:84-89.
    PubMed     Abstract available


  2. ACOSTA U, Bebia V, Torne A, Carreras-Dieguez N, et al
    Topographic mapping of pelvic and aortic lymph node metastases in stage IIIC1r locally advanced cervical cancer: A retrospective study by the Spain-GOG group.
    Gynecol Oncol. 2025;198:49-54.
    PubMed     Abstract available


  3. LEE JY, Boonyapipat S, Yuan G, Kim HS, et al
    AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer.
    Gynecol Oncol. 2025;198:25-32.
    PubMed     Abstract available


  4. GU J, Zheng W, Li F, Luo C, et al
    Redefining stage IVB cervical cancer: The unique prognosis of distant lymph node metastasis which is comparable to stage IIIC.
    Gynecol Oncol. 2025;198:17-24.
    PubMed     Abstract available


    April 2025
  5. BAE J, Kim U, Paik ES, Lim MC, et al
    Oncologic outcomes of minimally invasive surgery vs. abdominal hysterectomy in patients with low-risk, early-stage cervical cancer: A retrospective analysis of KGOG 1028 data based on SHAPE trial eligibility criteria.
    Gynecol Oncol. 2025;197:91-95.
    PubMed     Abstract available


  6. FRIEDMAN EL, Guo XM, Furey KB, Lee AJ, et al
    Temporal trends of sentinel lymph node biopsy without lymphadenectomy at cervical cancer surgery.
    Gynecol Oncol. 2025;196:182-191.
    PubMed     Abstract available


  7. BORCINOVA M, Kohler C, Nemejcova K, Zapardiel I, et al
    Preoperative tumour size assessment in patients with early-stage cervical cancer: Final results of the SENTIX study.
    Gynecol Oncol. 2025;196:160-167.
    PubMed     Abstract available


  8. WOLF B, Trantaki DS, Horn LC, Aktas B, et al
    Preoperative conization in cervical cancer patients undergoing open abdominal radical hysterectomy: Results from a propensity-score matched study.
    Gynecol Oncol. 2025;196:69-77.
    PubMed     Abstract available


  9. LEATH CA 3RD, Deng W, Mell LK, Richardson DL, et al
    Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
    Gynecol Oncol. 2025;195:122-133.
    PubMed     Abstract available


    March 2025
  10. LORUSSO D, Oaknin A, Borges GS, Damian F, et al
    Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial.
    Gynecol Oncol. 2025;196:28-35.
    PubMed     Abstract available


  11. KIM J, Jang J, Lim MC, Kim MH, et al
    Which factors predict the effectiveness of adjuvant treatment in patients with non-high-risk early-stage cervical cancer? Ancillary analysis of KGOG-1028.
    Gynecol Oncol. 2025;196:10-15.
    PubMed     Abstract available


  12. DE BONDT D, Naslazi E, Jansen E, Kupets R, et al
    Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies.
    Gynecol Oncol. 2025;195:134-143.
    PubMed     Abstract available


  13. CARTER J, Huang HQ, Monk BJ, Kim YB, et al
    Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278).
    Gynecol Oncol. 2025;195:50-58.
    PubMed     Abstract available


  14. COVENS A, Huang HQ, Monk BJ, Kim YB, et al
    Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278).
    Gynecol Oncol. 2025;195:59-65.
    PubMed     Abstract available


  15. VELASQUEZ J, Mohammed-Norgan M, Scheiber A, Chalif J, et al
    Cross-language insights: Comparing Spanish and English-language cervical cancer content on TikTok.
    Gynecol Oncol. 2025;194:131-136.
    PubMed     Abstract available


    February 2025
  16. WALKER AR, Leite S, Chen YS, Huepenbecker SP, et al
    Sentinel lymph node biopsy at the time of hysterectomy for early-stage cervical cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2025;195:1-5.
    PubMed     Abstract available


  17. MACDUFFIE E, Kernell C, George J, Bvochora-Nsingo M, et al
    Efficacy of induction chemotherapy during the COVID-19 pandemic for treatment of locally advanced cervical cancer in Botswana.
    Gynecol Oncol. 2025;194:91-97.
    PubMed     Abstract available


    January 2025
  18. KIM YJ, Lee J, Park S, Kim YM, et al
    The value of magnetic resonance imaging in predicting vesicovaginal fistula in cervical cancer with bladder invasion treated with definitive chemoradiotherapy.
    Gynecol Oncol. 2025;193:136-140.
    PubMed     Abstract available


  19. SCHAAFSMA M, Schuurman TN, Siebers AG, Bekkers RLM, et al
    Cost-effectiveness of an additional hysterectomy after initially conservative treatment for cervical adenocarcinoma in situ.
    Gynecol Oncol. 2025;193:113-118.
    PubMed     Abstract available


  20. LEIJTENS L, Piek J, Verrijssen AS, Rijkaart D, et al
    Thromboprophylaxis in patients with locally advanced cervical cancer treated with chemoradiation and brachytherapy.
    Gynecol Oncol. 2025;193:41-48.
    PubMed     Abstract available


    December 2024
  21. NGUYEN T, Yi Y, Morron S, Brittain D, et al
    Living in a food desert in Louisiana and its effects on gynecologic cancer outcomes.
    Gynecol Oncol. 2024;192:137-144.
    PubMed     Abstract available


  22. WONG TY, Adzibolosu NK, Mattei LH, Speak AC, et al
    Disparities in contemporary human papilloma virus vaccination uptake among adult women living in the United States: An All of Us Research Program study.
    Gynecol Oncol. 2024;191:100-105.
    PubMed     Abstract available


    November 2024
  23. DE JAEGHERE EA, Hamerlinck H, Tuyaerts S, Lippens L, et al
    Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial.
    Gynecol Oncol. 2024;191:275-286.
    PubMed     Abstract available


  24. JAIN D, Zaeim F, Wahidi M, Smith WJ, et al
    Cervical squamous cell carcinoma outcomes across continents: A retrospective study.
    Gynecol Oncol. 2024;190:272-282.
    PubMed     Abstract available


  25. CHOI YK, Lee JH, Kim YS, Wee CW, et al
    Mid-treatment MRI-based tumor response assessment for tumor recurrence and patient survival in locally advanced adenocarcinoma of the cervix: A retrospective multicenter study of KROG 23-03.
    Gynecol Oncol. 2024;190:222-229.
    PubMed     Abstract available


  26. NONZEE NJ, Thiel de Bocanegra H, Navarro S, Bastani R, et al
    Impact of management guidelines for abnormal cervical cytology on colposcopy procedure rates among young women.
    Gynecol Oncol. 2024;190:160-166.
    PubMed     Abstract available


    October 2024
  27. HUNSBERGER KS, Tewari KS, Monk BJ, Chase DM, et al
    Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;191:259-264.
    PubMed     Abstract available


  28. LI G, Li X, Yin R, Feng M, et al
    Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.
    Gynecol Oncol. 2024;191:165-171.
    PubMed     Abstract available


  29. ELAYAPILLAI SP, Dogra S, Lausen J, Parker M, et al
    ATR inhibition increases reliance on PARP-mediated DNA repair revealing an improved therapeutic strategy for cervical cancer.
    Gynecol Oncol. 2024;191:182-193.
    PubMed     Abstract available


  30. NG ZY, Manchanda R, Lopez A, Obermair A, et al
    The prognosis of stage IA cervical cancer: Subgroup analysis of the SCCAN study.
    Gynecol Oncol. 2024;191:95-99.
    PubMed     Abstract available


    September 2024
  31. LINDQUIST S, Kjaer SK, Frederiksen K, Ornskov D, et al
    Comparative analysis of HPV testing versus cytology in Danish cervical cancer screening: Insights from a large-scale implementation study.
    Gynecol Oncol. 2024;191:45-55.
    PubMed     Abstract available


  32. YANG X, Li C, Li Z, Du D, et al
    The clinical value of ultrasound-guided sacral anesthesia in Intracavitary and/or interstitial brachytherapy for cervical Cancer.
    Gynecol Oncol. 2024;191:31-36.
    PubMed     Abstract available


  33. FULLERTON R, Martell K, Khanolkar R, Phan T, et al
    Impact of immune, inflammatory and nutritional indices on outcome in patients with locally advanced cervical cancer treated with definitive (chemo)radiotherapy.
    Gynecol Oncol. 2024;190:291-297.
    PubMed     Abstract available


  34. NGUYEN L, Chung TH, Le YL, Reygaerts H, et al
    Hispanic individuals' cervical cancer screening disparities amidst the COVID-19 pandemic.
    Gynecol Oncol. 2024;190:243-249.
    PubMed     Abstract available


  35. MONK BJ, Tewari KS, Randall LM, Pothuri B, et al
    Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18.
    Gynecol Oncol. 2024;188:81-82.
    PubMed    


    August 2024
  36. LIM H, Kim SI, Kim MK, Yoon SH, et al
    Initial sarcopenia and body composition changes as prognostic factors in cervical cancer patients treated with concurrent chemoradiation: An artificial intelligence-based volumetric study.
    Gynecol Oncol. 2024;190:200-208.
    PubMed     Abstract available


  37. MILLER EA, Chowdhary B, Chapman-Davis E
    Beyond the decision: Reproductive justice and cervical cancer care in a post-Dobbs era.
    Gynecol Oncol. 2024;190:186-188.
    PubMed     Abstract available


  38. FRICOVA L, Kommoss S, Scambia G, Ferron G, et al
    Reproductive outcomes after fertility-sparing surgery for cervical cancer - results of the multicenter FERTISS study.
    Gynecol Oncol. 2024;190:179-185.
    PubMed     Abstract available


  39. CHUK E, Conway JL, Hanuschak J, Han K, et al
    Patient-reported sexual health outcomes of cervical cancer patients treated with definitive chemoradiation and MRI-guided brachytherapy.
    Gynecol Oncol. 2024;190:153-159.
    PubMed     Abstract available


  40. WAGAR MK, Patel UJ, Bharucha K, Heisler CA, et al
    Postoperative urinary retention by void trial methodology following radical hysterectomy for cervical cancer.
    Gynecol Oncol. 2024;190:90-95.
    PubMed     Abstract available


  41. FROEDING LP, Jensen PT
    Commentary on "Simple versus radical hysterectomy in women with low-risk cervical cancer" by Plante M. et al. published in The New England Journal of Medicine.
    Gynecol Oncol. 2024;189:137.
    PubMed    


  42. ADOLPH L, Mann A, Liu XQ, Roberts L, et al
    Follow-up of women with cervical adenocarcinoma in situ treated by conization: A single centre clinical experience.
    Gynecol Oncol. 2024;187:74-79.
    PubMed     Abstract available


    July 2024
  43. DA COSTA AABA, Souza RP, Pandolfi NC, de Souza Castro F, et al
    Should we consider progression-free survival benefits enough for drug approvals in locally advanced cervical cancer?
    Gynecol Oncol. 2024;189:109-110.
    PubMed    


  44. BERGSTEIN A, Huang Y, Hershman DL, Xu X, et al
    Impact of medicaid expansion on cervical cancer screening: A state-specific difference in difference analysis.
    Gynecol Oncol. 2024;189:49-55.
    PubMed     Abstract available


    June 2024
  45. KA K, Cordoba A, Cagetti LV, Schiappa R, et al
    Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group.
    Gynecol Oncol. 2024;188:90-96.
    PubMed     Abstract available


  46. KOCIAN R, Kohler C, Bajsova S, Jarkovsky J, et al
    Sentinel lymph node pathological ultrastaging: Final outcome of the Sentix prospective international study in patients with early-stage cervical cancer.
    Gynecol Oncol. 2024;188:83-89.
    PubMed     Abstract available


  47. WALKER CA, Edwards C, McIntire D, Makepeace L, et al
    Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer.
    Gynecol Oncol. 2024;188:22-26.
    PubMed     Abstract available


  48. O'CONNOR RM, Huang DS, Rimel BJ, Kim KH, et al
    Unmet financial needs among patients crowdfunding to support gynecologic cancer care.
    Gynecol Oncol. 2024;186:199-203.
    PubMed     Abstract available


  49. CHALIF J, Kistenfeger Q, Fulton J, Morton M, et al
    Diagnosis and management of gastric-type endocervical adenocarcinoma: A case report and review of the literature.
    Gynecol Oncol. 2024;185:165-172.
    PubMed     Abstract available


    May 2024
  50. PERSSON J, Luhrs O, Geppert B, Ekdahl L, et al
    A prospective study evaluating an optimized sentinel node algorithm in early stage cervical cancer: The PROSACC-study.
    Gynecol Oncol. 2024;187:178-183.
    PubMed     Abstract available


  51. HUNSBERGER KS, Treiman S, Monk BJ, Tewari KS, et al
    A systematic review of stage IVA cervical cancer treatment: Challenges in the management of an understudied group.
    Gynecol Oncol. 2024;187:120-127.
    PubMed     Abstract available


  52. CHIBA Y, Kojima Y, Yazaki S, Yoshida H, et al
    Trop-2 expression and the tumor immune microenvironment in cervical cancer.
    Gynecol Oncol. 2024;187:51-57.
    PubMed     Abstract available


  53. MACCHIA G, Cilla S, Pezzulla D, Campitelli M, et al
    Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer.
    Gynecol Oncol. 2024;184:16-23.
    PubMed     Abstract available


    April 2024
  54. VESZTERGOM D, Teglas G, Bahrehmand K, Torok A, et al
    Reducing radicality in fertility-sparing surgery is associated with improved in vitro fertilization outcome in early-stage cervical cancer: A national retrospective study.
    Gynecol Oncol. 2024;186:35-41.
    PubMed     Abstract available


    March 2024
  55. ROSS DH, Gomez K, Harmon G, Mysz ML, et al
    Evaluating outcomes and toxicities for a newly implemented MRI-based brachytherapy program for cervical cancer.
    Gynecol Oncol. 2024;183:33-38.
    PubMed     Abstract available


  56. GASS P, Thiel FC, Haberle L, Ackermann S, et al
    Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
    Gynecol Oncol. 2024;183:25-32.
    PubMed     Abstract available


    February 2024
  57. NICA A, Benseler A, Parbhakar A, Fortin LT, et al
    Robotic versus vaginal radical trachelectomy for reproductive-aged patients with early-stage cervical carcinoma: A multi-center cohort study.
    Gynecol Oncol. 2024;185:95-100.
    PubMed     Abstract available


  58. ROOF KA, Wichmann HK, Carlton LJ, Nguyen ML, et al
    Factors associated with loss to follow up after abnormal cervical cancer screening in pregnancy.
    Gynecol Oncol. 2024;185:46-50.
    PubMed     Abstract available


  59. KUCERA CW, Chappell NP, Tian C, Richardson MT, et al
    Survival disparities in non-Hispanic Black and White cervical cancer patients vary by histology and are largely explained by modifiable factors.
    Gynecol Oncol. 2024;184:224-235.
    PubMed     Abstract available


  60. DINICU AI, Dioun S, Wang Y, Huang Y, et al
    Survival rates in Hispanic/Latinx subpopulations with cervical cancer associated with disparities in guideline-concordant care.
    Gynecol Oncol. 2024;184:214-223.
    PubMed     Abstract available


  61. PELTECU G
    Eugen Bogdan Aburel, a pioneer of fertility sparing surgery.
    Gynecol Oncol. 2024;181:40-45.
    PubMed     Abstract available


    January 2024
  62. DORISMOND VG, Saraiya M, Gopalani SV, Soman A, et al
    Variation in cervical cancer screening test utilization and results in a United States-based program.
    Gynecol Oncol. 2024;184:96-102.
    PubMed     Abstract available


  63. BEFANO B, Wentzensen N, Lorey T, Poitras N, et al
    Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.
    Gynecol Oncol. 2024;184:89-95.
    PubMed     Abstract available


  64. MANNING-GEIST B, Grace MA, Sonoda Y
    Trachelectomy and fertility-sparing procedures for early-stage cervical cancer: A state of the science review.
    Gynecol Oncol. 2024;181:179-182.
    PubMed    


  65. LEE SS, Gold HT, Kwon SC, Pothuri B, et al
    Guideline concordant care for patients with locally advanced cervical cancer by disaggregated Asian American and Native Hawaiian/Pacific Islander groups: A National Cancer Database Analysis.
    Gynecol Oncol. 2024;182:132-140.
    PubMed     Abstract available


  66. CHOI KH, Lee HC, Kim YS, Park W, et al
    Diagnostic assessments and treatment results of well-differentiated gastric-type adenocarcinoma of the uterine cervix (Adenoma malignum): A multicenter retrospective analysis of KROG 22-03 study.
    Gynecol Oncol. 2024;182:45-50.
    PubMed     Abstract available


  67. FRIEDMAN CF, D'Souza A, Bello Roufai D, Tinker AV, et al
    Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
    Gynecol Oncol. 2024;181:162-169.
    PubMed     Abstract available


    December 2023
  68. TJIOE KC, Miranda-Galvis M, Johnson MS, Agrawal G, et al
    The interaction between social determinants of health and cervical cancer survival: A systematic review.
    Gynecol Oncol. 2023;181:141-154.
    PubMed     Abstract available


  69. HALLE MK, Bozickovic O, Forsse D, Wagner-Larsen KS, et al
    Clinicopathological and radiological stratification within FIGO 2018 stages improves risk-prediction in cervical cancer.
    Gynecol Oncol. 2023;181:110-117.
    PubMed     Abstract available


  70. RIVES TA, Orellana TJ, Mumford BS, Sukumvanich P, et al
    The role of obesity in treatment planning for early-stage cervical cancer.
    Gynecol Oncol. 2023;181:60-67.
    PubMed     Abstract available


  71. URBUTE A, Frederiksen K, Thomsen LT, Kesmodel US, et al
    Overweight and obesity as risk factors for cervical cancer and detection of precancers among screened women: A nationwide, population-based cohort study.
    Gynecol Oncol. 2023;181:20-27.
    PubMed     Abstract available


  72. VAHTERISTO M, Leinonen MK, Sarkeala T, Anttila A, et al
    Similar effectiveness with primary HPV and cytology screening - Long-term follow-up of randomized cervical cancer screening trial.
    Gynecol Oncol. 2023;180:146-151.
    PubMed     Abstract available


  73. HSIEH K, Bloom JR, Dickstein DR, Hsieh C, et al
    Dose and fractionation regimen for brachytherapy boost in cervical cancer in the US.
    Gynecol Oncol. 2023;180:55-62.
    PubMed     Abstract available


  74. RAI R, Lightfoot S, Benbrook DM
    Manipulation of metabolic responses enhances SHetA2 efficacy without toxicity in cervical cancer cell lines and xenografts.
    Gynecol Oncol. 2023;180:44-54.
    PubMed     Abstract available


  75. SAMMOURI J, Venkatesan AM, Lin LL, Jhingran A, et al
    Management and long-term clinical outcomes of patients with stage IVA cervical cancer with bladder involvement.
    Gynecol Oncol. 2023;180:24-34.
    PubMed     Abstract available


  76. LONG E, Macdonald MC, Parker VL, Lyon R, et al
    Factors associated with failed 'test of cure' in the NHS Cervical Screening Programme: A retrospective cohort study.
    Gynecol Oncol. 2023;179:158-163.
    PubMed     Abstract available


    November 2023
  77. NASIOUDIS D, Gysler S, Latif N, Cory L, et al
    Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
    Gynecol Oncol. 2023;180:1-5.
    PubMed     Abstract available


  78. HERMANN CE, Patel JM, Boyd L, Growdon WB, et al
    Let's chat about cervical cancer: Assessing the accuracy of ChatGPT responses to cervical cancer questions.
    Gynecol Oncol. 2023;179:164-168.
    PubMed     Abstract available


  79. GIRDA E, Randall LM, Chino F, Monk BJ, et al
    Cervical cancer treatment update: A Society of Gynecologic Oncology clinical practice statement.
    Gynecol Oncol. 2023;179:115-122.
    PubMed     Abstract available


  80. KUMAR R, Sherwani Z, Lopez M, Vergalasova I, et al
    Disparities in brachytherapy utilization in cervical cancer in the United States: A comprehensive literature review.
    Gynecol Oncol. 2023;179:79-84.
    PubMed     Abstract available


  81. WICKENHEISSER NE, Dillon M, Broadwater G, Zacherl K, et al
    Radical hysterectomy case volume and cervical cancer treatment in the era of COVID-19: A multi-site analysis of National Cancer Institute-designated Comprehensive Cancer Centers.
    Gynecol Oncol. 2023;179:70-78.
    PubMed     Abstract available


  82. SUMMEY R, Benoit M, Williams-Brown MY
    Survival differences by race and surgical approach in early-stage operable cervical Cancer.
    Gynecol Oncol. 2023;179:63-69.
    PubMed     Abstract available


  83. CHEN F, Zhang GN, Lei W, Zhou SG, et al
    Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study.
    Gynecol Oncol. 2023;178:8-13.
    PubMed     Abstract available


    October 2023
  84. BAETEN IGT, Hoogendam JP, Schreuder HWR, Jurgenliemk-Schulz IM, et al
    Introducing a novice surgeon to an experienced robotic gynaecological oncology team: An observational cohort study on the impact of a structured curriculum on outcomes of cervical cancer surgery.
    Gynecol Oncol. 2023;178:153-160.
    PubMed     Abstract available


  85. CHAPMAN GC, Smrz SA, Gordon JC, Lynam SK, et al
    Gynecologic cancer care in the first year of the COVID-19 pandemic.
    Gynecol Oncol. 2023;178:138-144.
    PubMed     Abstract available


    September 2023
  86. AGUSTI N, Viveros-Carreno D, Mora-Soto N, Ramirez PT, et al
    Diagnostic accuracy of sentinel lymph node frozen section analysis in patients with early-stage cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;177:157-164.
    PubMed     Abstract available


  87. LEE HC, Jeong JW, Lee JH, Kim SH, et al
    High-dose (60 Gy) intensity-modulated radiotherapy with concurrent weekly cisplatin followed by intracavitary radiation in locally advanced cervical cancer: A phase II prospective clinical trial.
    Gynecol Oncol. 2023;177:142-149.
    PubMed     Abstract available


  88. PRAISS AM, Allison D, Tessier-Cloutier B, Flynn J, et al
    Extensive versus focal lymphovascular invasion in squamous cell carcinoma of the cervix: A comprehensive international, multicenter, retrospective clinicopathologic study.
    Gynecol Oncol. 2023;176:147-154.
    PubMed     Abstract available


    August 2023
  89. KOROMPELIS P, Rundle S, Cassar V, Ratnavelu N, et al
    "Conservative surgical approaches for small volume FIGO stage IB1 cervical cancer. Updated survival and obstetric outcomes of an expanded cohort".
    Gynecol Oncol. 2023;176:155-161.
    PubMed     Abstract available


    July 2023
  90. KONG TW, Kim J, Son JH, Lee AJ, et al
    Is minimally invasive radical surgery safe for patients with cervical cancer
    Gynecol Oncol. 2023;176:122-129.
    PubMed     Abstract available


  91. EIDE AJ, Halle MK, Lura N, Fasmer KE, et al
    Visceral fat percentage for prediction of outcome in uterine cervical cancer.
    Gynecol Oncol. 2023;176:62-68.
    PubMed     Abstract available


  92. KAHVECIOGLU A, Gurlek E, Yedekci FY, Sari SY, et al
    Simultaneous integrated or sequential boost to clinically involved lymph nodes in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy.
    Gynecol Oncol. 2023;176:10-15.
    PubMed     Abstract available


    June 2023
  93. KONSKI A, Deshmukh S, Klopp AH, Yeung AR, et al
    Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203.
    Gynecol Oncol. 2023;175:176-181.
    PubMed     Abstract available


  94. MAH SJ, Carter Ramirez DM, Eiriksson LR, Schnarr K, et al
    Palliative care utilization across health sectors for patients with gynecologic malignancies in Ontario, Canada from 2006 to 2018.
    Gynecol Oncol. 2023;175:169-175.
    PubMed     Abstract available


  95. LI J, Xue X, Zhang Y, Ding F, et al
    The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer.
    Gynecol Oncol. 2023;175:133-141.
    PubMed     Abstract available


  96. MORTON M, Haight PJ, Khadraoui W, Backes F, et al
    "More than a song and dance": Exploration of patient perspectives and educational quality of gynecologic cancer content on TikTok.
    Gynecol Oncol. 2023;175:81-87.
    PubMed     Abstract available


  97. KULKARNI A, Chen L, Gockley A, Khoury-Collado F, et al
    Patterns of cervical cancer screening follow-up in the era of prolonged screening intervals.
    Gynecol Oncol. 2023;175:53-59.
    PubMed     Abstract available


  98. LEVINE MD, Barrington DA, Meade CE, Lammers SM, et al
    Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes.
    Gynecol Oncol. 2023;173:15-21.
    PubMed     Abstract available


    May 2023
  99. SCHIFFMAN M, Mirabello L, Egemen D, Befano B, et al
    The combined finding of HPV 16, 18, or 45 and cytologic Atypical Glandular Cells (AGC) indicates a greatly elevated risk of in situ and invasive cervical adenocarcinoma.
    Gynecol Oncol. 2023;174:253-261.
    PubMed     Abstract available


  100. KIM NR, Kim SI, Suh DH, Kim HS, et al
    Survival outcomes of laparoscopic versus open radical hysterectomy in early cervical cancer with incidentally identified high-risk factors.
    Gynecol Oncol. 2023;174:224-230.
    PubMed     Abstract available


  101. HAN L, Chen Y, Zheng A, Chen H, et al
    Effect of preoperative cervical conization before hysterectomy on survival and recurrence of patients with cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;174:167-174.
    PubMed     Abstract available


  102. VERGOTE I, Van Nieuwenhuysen E, Casado A, Laenen A, et al
    Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer.
    Gynecol Oncol. 2023;174:80-88.
    PubMed     Abstract available


  103. ROBOVA H, Rob L, Halaska MJ, Drozenova J, et al
    Twenty years of experience with less radical fertility-sparing surgery in early-stage cervical cancer: Pregnancy outcomes.
    Gynecol Oncol. 2023;174:76-79.
    PubMed     Abstract available


  104. DI DONATO V, Bogani G, Casarin J, Ghezzi F, et al
    Ten-year outcomes following laparoscopic and open abdominal radical hysterectomy for "low-risk" early-stage cervical cancer: A propensity-score based analysis.
    Gynecol Oncol. 2023;174:49-54.
    PubMed     Abstract available


  105. STOLER MH, Parvu V, Yanson K, Andrews J, et al
    Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.
    Gynecol Oncol. 2023;174:68-75.
    PubMed     Abstract available


  106. PIEDIMONTE S, Helpman L, Pond G, Nelson G, et al
    Surgical margin status in relation to surgical approach in the management of early-stage cervical Cancer: A Canadian cervical Cancer collaborative (4C) study.
    Gynecol Oncol. 2023;174:21-27.
    PubMed     Abstract available


  107. FUREY KB, Anderson ZS, Kuznicki ML, Klar M, et al
    Increasing trends of cervical conization with lymph node evaluation for fertility-sparing surgery in early cervical cancer.
    Gynecol Oncol. 2023;173:122-129.
    PubMed     Abstract available


    April 2023
  108. KIM SI, Nam SH, Hwangbo S, Kim Y, et al
    Conization before radical hysterectomy in patients with early-stage cervical cancer: A Korean multicenter study (COBRA-R).
    Gynecol Oncol. 2023;173:88-97.
    PubMed     Abstract available


  109. GARCIA-SAYRE J, Lin YG, Matuso K, Tsao-Wei DD, et al
    Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer.
    Gynecol Oncol. 2023;173:49-57.
    PubMed     Abstract available


  110. CIBULA D
    The group with the most heterogenous treatment among patients with cervical cancer.
    Gynecol Oncol. 2023 Apr 17:S0090-8258(23)00169.
    PubMed    


    March 2023
  111. TEWARI KS, Sill MW, Birrer MJ, Penson RT, et al
    Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical Cancer: A NRG oncology randomized study.
    Gynecol Oncol. 2023;171:141-150.
    PubMed     Abstract available


  112. MOOLENAAR LR, van Rangelrooij LE, van Poelgeest MIE, van Beurden M, et al
    Clinical outcomes of pelvic exenteration for gynecologic malignancies.
    Gynecol Oncol. 2023;171:114-120.
    PubMed     Abstract available


  113. STOLER MH, Wright TC Jr, Parvu V, Yanson K, et al
    Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial.
    Gynecol Oncol. 2023;170:143-152.
    PubMed     Abstract available


    February 2023
  114. BENBROOK DM, Deng W, Gold MA, Rai R, et al
    Association of Sialyl Tn antigen with cervical cancer lymph node status: An NRG oncology/GOG study.
    Gynecol Oncol. 2023;171:67-75.
    PubMed     Abstract available


  115. KIM C, Salvo G, Ishikawa M, Chen TC, et al
    The role of postoperative radiation after radical hysterectomy for women with early-stage neuroendocrine carcinoma of the cervix: A meta-analysis.
    Gynecol Oncol. 2023;170:328-332.
    PubMed     Abstract available


  116. KAUR A, Wang S, Kumar A
    Impact of racial disparities on potential years of life lost due to gynecologic cancer in the United States: Trends from 1975 to 2017 based on SEER database.
    Gynecol Oncol. 2023;170:266-272.
    PubMed     Abstract available


  117. HOLLOWAY SB, Mercadel AJ, Miller DS, Lea JS, et al
    Isolated para-aortic nodal recurrence after treatment of early stage cervical carcinoma.
    Gynecol Oncol. 2023;170:248-253.
    PubMed     Abstract available


    January 2023
  118. LU L, Liu T, Wang S, Li J, et al
    Joint detection of multiple HPV-testing technologies and evaluation of clinicopathological characteristics discriminate between HPV-independent and low-copy HPV-associated cervical squamous cell carcinoma (CSCC) -an analysis of 3869 cases.
    Gynecol Oncol. 2023;170:59-69.
    PubMed     Abstract available


    September 2022
  119. HOLM J, Gerke O, Vilstrup MH, Spasojevic D, et al
    Improved stratification of stage-specific survival for cervical uterine cancer by integrating FDG-PET/CT and MRI for lymph node staging in 2018 FIGO classification.
    Gynecol Oncol. 2022 Sep 28. pii: S0090-8258(22)01841.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Cervical Cancer is free of charge.